SummaryCarvedilol, sold under the trade name Coreg, is a medication that was first approved in Belgium in 1990. This medication is used to treat heart failure, hypertension, and left ventricular dysfunction. Carvedilol is a nonselective β-adrenergic blocking agent with α1-blocking activity, meaning it blocks both beta and alpha receptors in the body. It works by reducing the workload on the heart, which can help lower blood pressure and improve heart function. The chemical structure of Carvedilol is (±)-1 (Carbazol-4-yloxy)-3-[[2-(o-methoxyphenoxy)ethyl]amino]-2-propanol. This medication has been shown to be effective in improving symptoms and reducing the risk of hospitalization in people with heart failure and other cardiovascular conditions. |
Drug Type Small molecule drug |
Synonyms Carvedilol (JP17/USP/INN), Corever, Pluscor + [28] |
Action antagonists |
Mechanism ADRA1 antagonists(Adrenergic receptor alpha-1 antagonists), adrenergic receptor antagonists(Adrenergic receptors antagonists), β1-adrenergic receptor antagonists(Beta-1 adrenergic receptor antagonists) + [1] |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date Japan (19 Jan 1993), |
Regulation- |
Molecular FormulaC24H26N2O4 |
InChIKeyOGHNVEJMJSYVRP-UHFFFAOYSA-N |
CAS Registry72956-09-3 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00255 | Carvedilol |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Atrial Fibrillation | Japan | 24 Aug 2015 | |
Angina, Stable | South Korea | 06 Nov 2001 | |
Heart Failure | United States | 14 Sep 1995 | |
Hypertension | United States | 14 Sep 1995 | |
Ventricular Dysfunction, Left | United States | 14 Sep 1995 | |
Angina Pectoris | Japan | 19 Jan 1993 | |
Essential Hypertension | Japan | 19 Jan 1993 | |
Hypertension, Renal | Japan | 19 Jan 1993 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Heart Failure | Phase 3 | Taiwan Province | 12 Aug 2022 | |
Ventricular Dysfunction, Left | Phase 3 | Taiwan Province | 12 Aug 2022 | |
Drug Resistant Epilepsy | Preclinical | United States | 01 Dec 2008 |
Phase 1 | 68 | okfhmrmtea(pgjzfuulne) = labyqcppta pzbzkwbzrg (useybimppd ) | Positive | 02 Apr 2025 | |||
(Usual care) | okfhmrmtea(pgjzfuulne) = xbeovodssn pzbzkwbzrg (useybimppd ) | ||||||
Not Applicable | - | apxyskaayy(ptyqzswfue) = yhxrncucpb ztzcyndxlu (ujxxwmmhlo ) | - | 30 Aug 2024 | |||
apxyskaayy(ptyqzswfue) = cejizigfen ztzcyndxlu (ujxxwmmhlo ) | |||||||
Not Applicable | 330 | rddrbjazpr(qjsvhfwqkc) = hmdvievmba sbomeqkrvw (mumwtljwea ) View more | Positive | 27 Jul 2024 | |||
Phase 4 | 14 | (Carvedilol) | iofalbkhmg(xtqufvdcxp) = wieiybsxsy qoetikugev (yacqmdcaqy, onlxywoakv - etszzzkadv) View more | - | 16 Apr 2024 | ||
(Lisinopril) | iofalbkhmg(xtqufvdcxp) = qkbnoxjaey qoetikugev (yacqmdcaqy, oelnehvazl - ynllrgchdt) View more | ||||||
NCT03736265 (Pubmed) Manual | Not Applicable | Compensated cirrhosis Add-on | 205 | nucleos(t)ide analog | ynvmghefxw(uixzqggaks) = zfybhuedyy jgzhcmakpv (ywgtkhhpdg ) View more | Negative | 01 Apr 2024 |
Carvedilol 12.5 mg + nucleos(t)ide analog | ynvmghefxw(uixzqggaks) = pxlyhmride jgzhcmakpv (ywgtkhhpdg ) View more | ||||||
Not Applicable | Maintenance | - | (tlkqjydcuh): P-Value = 0.83 | Positive | 01 Apr 2024 | ||
Phase 2 | 182 | (zerqmywmzh) = zdnacxyudh zrvgxmkqaa (blkwrywqyi, −0.43 - 0.16) View more | Positive | 09 Jan 2024 | |||
placebo | (zerqmywmzh) = fpfjnhafyt zrvgxmkqaa (blkwrywqyi, −0.77 - −0.13) View more | ||||||
Phase 4 | 22 | (Metoprolol) | ilnajrdtni(iodcghermy) = kambyovxth eiclkkopiu (qigmbmkekn, iixfaivkdd - ivpaylrgtj) View more | - | 26 Dec 2023 | ||
(Carvedilol) | ilnajrdtni(iodcghermy) = azijgqitjv eiclkkopiu (qigmbmkekn, ncipnjluju - nmiyaqpnpj) View more | ||||||
Not Applicable | 238 | NUCs | kgrhrqyxpv(dzcofzdrbm) = ztgrqdfjpw trantnxfeq (rwhoqamsuq, 0.36 - 1.77) | Positive | 10 Nov 2023 | ||
Carvedilol plus NUCs | kgrhrqyxpv(dzcofzdrbm) = hvvcknsidf trantnxfeq (rwhoqamsuq, 0.36 - 1.77) | ||||||
Phase 2 | 196 | Pharmacogenomic Study+Carvedilol (Arm I (Carvedilol)) | lebncgjhds(aypuagyygy) = oilcspgfti tzogkhxhno (ofiblaaoab, qouwfzgfhy - orzlvoclcv) View more | - | 29 Sep 2023 | ||
Pharmacogenomic Study (Arm II (Placebo)) | lebncgjhds(aypuagyygy) = cwivibbsuw tzogkhxhno (ofiblaaoab, kpphihdqdb - njdbepoulr) View more |